Dublin, Jan. 09, 2017 -- Research and Markets has announced the addition of the "Oncology Startups 2017" report to their offering.
Oncology Startups 2017, is the first unique attempt to provide highly precise and updated information on newly established cancer drug developing companies and enables their early identification.
The Report illuminates Top 500 cancer drug developers established during 2010-2016, and without any doubt is one of the world's largest focused data coverage on Active Drug Developers working with numerous methodologies to target cancer.
Oncology Startups 2017, is unique in many aspects as it for the first time provides cancer startups ranking, based on individual company's overall score on five major parameters- venture funding, key management, technology, deals & partnerships and cancer focused pipeline. The report, also provides quick infographics and final intelligence to keep information on fingertips.
Key Highlights:
- Startups Focused - Highly focused, includes only startups involved directly in Cancer Drug Discovery & established on and after 2010.
- Worldwide Geographic Coverage - Covers Top 500 startups from 28 countries, developing 628 cancer targeting therapies.
- Top 500 Ranking -For better, quicker and focused actionable intelligence on startups.
- Vast ImmunoOncology Coverage - Special Coverage, Infographics & Intelligence on 225 Top Emerging Immunooncology Startups.
- Technology / Drug Pipeline - Details on Individual Startup's proprietary Technologies with its Active Cancer Pipeline and University / Institutes Collaborations.
- Strategic Moves & Advantages- Quickly Identify the key strategic moves a startup is taking to be more innovative, also identify its strategic advantages, that will boost its growth going forward.
- Venture Funding / Partnering - Monitor Individual Startup's Various Funding Rounds (Private / Govt. ). Its current Partnering Status with CROs / Research Institutes / Big Pharma.
- Key Management Contacts - Big Time Saver - Key Management Details / Contacts / e-mails / LinkedIn ... all at one place
Finally, the report is based on selecting Top 500 Active Oncology Drug Developers, selected from over 700+ companies established during the duration. Also, report covers only active cancer targeting (treatment) companies excluding Merged, Dormant or Simply Idea based companies. The report does not includes cancer diagnostic and cancer pain management companies.
Oncology Startups 2017, will help various organizations working on cancer research, to supercharge with lots of new decision making information and jumpstart their current partnering/marketing efforts.
Key Topics Covered:
List of Top 500 Oncology Startup (Drug Developer) Companies
Section A :- Oncology Startups 2017 - Top 500 Active Drug Developers' Summary
Section B :- Oncology Startups 2017 - Venture Funding & Big Pharma Partnering & Deals with Startups
Section C :- Oncology Startups 2017 - Top 500 Companies Profiles
Appendix A: Country Wise List of Top 500 Oncology Startup Companies
Appendix B: Complete 628 Molecules List, along with their Developer's Name
Companies Mentioned
- AADI, LLC
- AB Initio Biotherapeutics, Inc.
- ABBA Therapeutics AG
- Accuronix Therapeutics, Inc.
- Acerta Pharma B.V
- ADC Therapeutics Sarl
- Adgero Biopharmaceuticals, Inc.
- Adheren, Inc.
- Adicet Bio, Inc.
- - AdiuTide Pharmaceuticals GmbH
- Aeglea BioTherapeutics Holdings LLC
- Affilogic
- Agalimmune Ltd.
- Agilvax, Inc.
- AiVita Biomedical, Inc.
- Akshaya Bio Inc.
- Alexo Therapeutics, Inc.
- Alissa Pharma LLC
- Allomek Therapeutics LLC
- AlloOnc Corporation
- Amal Therapeutics S.A.
- Amcure GmbH
- Amphivena Therapeutics, Inc.
- Andarix Pharmaceuticals, Inc.
- Annam Pharma, Inc.
and many more.
For more information about this report visit http://www.researchandmarkets.com/research/tglc3s/oncology_startups
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Business, Oncology


Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 



